Smart hardware for injury recovery.
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about Penta Medical (S18).
Penta Medical developed portable hardware intended to direct infrared light toward injured tissue, paired with software for recording sessions, pain, and adherence. The company participated in Y Combinator's Summer 2018 batch and described itself as smart hardware for injury recovery.[1]
Waterloo and founder materials document the concept, an early athletics feedback partner, and a professional athlete recovery case that brought attention to the product. They do not establish clinical efficacy, regulatory authorization, commercial scale, or the company's eventual outcome. No Penta-specific peer-reviewed trial, regulator record, reliable financial metric, shutdown announcement, or asset disposition was found.
Alexa Roeper is the clearest documented founder associated with Penta Medical. Her project archive describes the portable light-based device and companion application.[2] The complete legal founder roster and incorporation date were not established, and secondary founder lists conflict with the primary Roeper material.
Penta emerged from the University of Waterloo entrepreneurship environment and later joined YC S18. The observed sources do not establish the final product name, complete specifications, patents, or manufacturing partner.
The hardware concept used photoactive fabric and wearable LED pods to apply or reflect infrared light toward an injured area.[3] Roeper's archive describes a portable device paired with an application for treatment-session and soft-tissue-injury monitoring, including pain and compliance tracking.[2]
Portability and adherence records were presented as differences from clinic-based light-therapy equipment. The observed material does not establish final technical specifications, production readiness, safety testing, or a legally marketed product.
Penta targeted sports-medicine teams and clinicians, where athlete availability carries competitive and financial value.[4]
No reliable market-size, customer-count, unit-sales, pricing, or revenue evidence was found. A named athletics partner shows that development progressed beyond a bare pitch, not that procurement was repeatable.
Penta positioned portability and software tracking against clinic-based light-therapy equipment. The source packet does not provide a verified competitor set, comparative performance study, reimbursement pathway, or purchasing analysis.
No documented pricing or revenue model was recovered. The likely commercial questions for wearable medical hardware include manufacturing, servicing, clinical sales, reimbursement, and support, but the evidence does not show how Penta planned to address them.
No reliable record establishes later funding, revenue, unit economics, manufacturing cost, customer contracts, or reimbursement. Those omissions prevent a responsible assessment of commercial viability.
The strongest documented traction is Michigan State University Athletics as an early customer and feedback partner, plus reported exposure through a professional baseball recovery case.[4] University documentation also shows that the product concept received institutional attention.
These facts do not establish therapeutic benefit, paid deployment, repeat purchases, or commercial scale. No durable operating metric was found.
There is not enough evidence for a failure mechanism. Medical hardware can face certification, quality, safety, manufacturing, liability, reimbursement, and clinical-sales burdens, but no source establishes which, if any, affected Penta.
Public descriptions used efficacy-oriented language. The bounded research found no Penta-specific peer-reviewed outcome study, registered clinical trial, FDA clearance or approval, Health Canada device licence, or confirmed classification. General photobiomodulation research cannot prove that Penta's particular device was safe, effective, or legally marketed.
Read the complete post-mortem, the rebuild playbook, and the exact reasons Penta Medical is still worth studying now.